Prospective evaluation of the contribution of K-ras mutational analysis and CA 19.9 measurement to cytological diagnosis in patients with clinical suspicion of pancreatic cancer

被引:13
作者
Urgell, E
Puig, P
Boadas, J
Capellà, G
Queraltó, JM
Boluda, R
Antonijuan, A
Farré, A
Lluís, F
González-Sastre, F
Mora, J
机构
[1] Hosp Santa Cruz & San Pablo, Dept Clin Biochem, E-08025 Barcelona, Spain
[2] Hosp Santa Cruz & San Pablo, Dept Gastroenterol, E-08025 Barcelona, Spain
[3] Inst Catala Oncol, Lhospitalet De Llobregat 08907, Spain
[4] Hosp Santa Cruz & San Pablo, Gastrointestinal Res Lab, E-08025 Barcelona, Spain
[5] Hosp Santa Cruz & San Pablo, Dept Surg, E-08025 Barcelona, Spain
关键词
CA; 19.9; K-ras; pancreatic neoplasm; chronic pancreatitis; cytology; pancreatic juice; fine needle aspirates (FNA);
D O I
10.1016/S0959-8049(00)00288-4
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The aim of this study was to prospectively evaluate the diagnostic contribution of the detection of K-ins mutation and measurement of serum CA 19.9 concentrations to cytological diagnosis in patients with clinical suspicion of pancreatic cancer. These patients had either the presence or absence of a pancreatic mass as determined by imaging procedures. A total of 156 consecutive patients with clinical suspicion of pancreatic cancer or for confirmation and follow-up of their chronic pancreatitis disease were included: 84 patients presenting a pancreatic mass (group 1) and 72 patients without a pancreatic mass (group 2). K-ras mutations were detected by a restriction fragment length polymorphism/polymerase chain reaction (RFLP/PCR) method and CA 19.9 by an immunoluminometric assay. When a pancreatic mass was present, cytology offered a high sensitivity, but with a significant number of inconclusive results and K-ras mutational analysis offered a highly specific test. In the absence of a pancreatic mass, CA 19.9 (cut-off 100 U/ml) increased the sensitivity of the diagnosis by cytology and K-ras mutational analysis did not add significant information. Thus both tests contribute to the clinical decision process when pancreatic cancer is clinically suspected and the cytological report is not conclusive. (C) 2000 Elsevier Science Ltd. All rights reserved.
引用
收藏
页码:2069 / 2075
页数:7
相关论文
共 33 条
[1]   IDENTIFICATION OF K-RAS MUTATIONS IN PANCREATIC-JUICE IN THE EARLY DIAGNOSIS OF PANCREATIC-CANCER [J].
BERTHELEMY, P ;
BOUISSON, M ;
ESCOURROU, J ;
VAYSSE, N ;
RUMEAU, JL ;
PRADAYROL, L .
ANNALS OF INTERNAL MEDICINE, 1995, 123 (03) :188-191
[2]   K-ras mutations in DNA extracted from the plasma of patients with pancreatic carcinoma:: Diagnostic utility and prognostic significance [J].
Castells, A ;
Puig, P ;
Móra, J ;
Boadas, J ;
Boix, L ;
Urgell, E ;
Solé, M ;
Capellà, G ;
Lluis, F ;
Fernández-Cruz, L ;
Navarro, S ;
Farré, A .
JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (02) :578-584
[3]  
Clave P, 1999, Gastroenterol Hepatol, V22, P335
[4]  
DIGIUSEPPE JA, 1994, AM J PATHOL, V144, P889
[5]  
FREBOURG T, 1988, CANCER-AM CANCER SOC, V62, P2287, DOI 10.1002/1097-0142(19881201)62:11<2287::AID-CNCR2820621103>3.0.CO
[6]  
2-H
[7]   Long-term follow-up of patients with chronic pancreatitis and K-ras gene mutation detected in pancreatic juice [J].
Furuya, N ;
Kawa, S ;
Akamatsu, T ;
Furihata, K .
GASTROENTEROLOGY, 1997, 113 (02) :593-598
[8]   EVALUATION OF CA 19-9 AS A SERUM TUMOR-MARKER IN PANCREATIC-CANCER [J].
HAGLUND, C ;
ROBERTS, PJ ;
KUUSELA, P ;
SCHEININ, TM ;
MAKELA, O ;
JALANKO, H .
BRITISH JOURNAL OF CANCER, 1986, 53 (02) :197-202
[9]  
JIANG W, 1989, ONCOGENE, V4, P923
[10]  
Kim HJ, 1999, AM J GASTROENTEROL, V94, P1941